Latest Breaking News On - Increasing serum potassium - Page 2 : comparemela.com

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

New zealandThomas hutterEmmanuelle lecomte brissetDeric dubeEuropean unionDrug administrationTravere therapeutics incExchange commissionEuropean medicines agencyFresenius medical careEuropean commissionCommittee for medicinal products human useAnnounce sparsentan receives positiveMedicinal productsHuman useTravere therapeutics

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in JapanSAN DIEGO, Jan. 25, 2024 Travere.

South koreaRepublic ofDeric dubeCatalys pacificRenalys pharmaRenalys pharma incTravere therapeutics incDevices agencyExchange commissionMedical devices agencySoutheast asianTravere therapeuticsImportant safetyEndothelin receptor antagonistsUpper limitFetal toxicity

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South koreaRepublic ofRenalys pharmaCatalys pacificDeric dubeExchange commissionTravere therapeutics incRenalys pharma incDevices agencyTherapeutics announces licensing agreementCommercialize sparsentanSoutheast asianMedical devices agencyTravere therapeuticsImportant safetyEndothelin receptor antagonists

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaRepublic ofDeric dubeRenalys pharmaCatalys pacificRenalys pharma incExchange commissionTravere therapeutics incDevices agencyMedical devices agencySoutheast asianTravere therapeuticsImportant safetyEndothelin receptor antagonistsUpper limitFetal toxicity

Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

After meeting with the FDA, Company to submit a supplemental New Drug Application to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® in IgAN to full approval .

Deric dubeGlobenewswire incDrug administrationTravere therapeutics incExchange commissionNew drug applicationImportant safetyEndothelin receptor antagonistsUpper limitFetal toxicityKidney injuryAngiotensin systemAcid reducing agentsSteroidal anti inflammatory agentsIncluding selectiveIncreasing serum potassium